The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that FORZINITY (elamipretide), approved September 19, 2025, manufactured by Stealth BioTherapeutics Inc., meets the criteria for a priority review voucher.
This is a notice published in the Federal Register by Health and Human Services Department, Food and Drug Administration. Notices communicate information, guidance, or policy interpretations but may not create new binding obligations.
This document is classified as a notice. It may or may not create enforceable regulatory obligations depending on its specific content.
Notice.
No specific effective date is indicated. Check the full text for date provisions.
| Document Number | 2025-23409 |
| FR Citation | 90 FR 59530 |
| Type | Notice |
| Published | Dec 19, 2025 |
| Effective Date | - |
| RIN | - |
| Docket ID | Docket No. FDA-2025-N-4683 |
| Pages | 59530–59530 (1 pages) |
| Text Fetched | No |
| Part | Name | Agency |
|---|---|---|
| No linked CFR parts | ||
| Type | Proposed | Final | Method | Conf |
|---|---|---|---|---|
| No paired documents | ||||
The full text for this document hasn't been fetched yet. The system will automatically retrieve it during the next processing cycle.